The active compound — guanidinoethylbenzylamino imidazopyridine acetate — selectively blocks the growth of harmful bacteria such as Porphyromonas gingivalis. (iStock)
Researchers in Germany have developed a targeted approach to preventing periodontitis by selectively inhibiting disease-causing bacteria while preserving the healthy oral microbiome.
Scientists at the Fraunhofer Institute for Cell Therapy and Immunology (IZI) identified a compound that blocks the growth of key periodontal pathogens such as Porphyromonas gingivalis, without eliminating beneficial bacteria that maintain microbial balance in the mouth.
“Rather than simply killing gingivitis pathogens, it inhibits their growth,” said Stephan Schilling, head of molecular drug biochemistry and therapy development at Fraunhofer IZI, noting the strategy supports long-term microbial stability.
Periodontitis affects a significant portion of the global population and has been linked to systemic conditions including diabetes, cardiovascular disease and Alzheimer’s disease. The oral microbiome itself contains more than 700 bacterial species, though only a small subset contributes to disease.
Related: Selective toothpaste therapy: The therapeutic value of various toothpaste ingredients
Related: Scientists explore using hair keratin in toothpaste to repair tooth enamel
Related: Scientists think toothpaste potential after discovering natural compound that destroys dental plaque
The issue with conventional products
Conventional treatments — including antiseptic mouthwashes and chlorhexidine-based products — broadly kill bacteria, disrupting the microbial ecosystem. While these approaches can temporarily reduce pathogenic load, they often allow harmful bacteria to re-establish dominance during recolonization, perpetuating inflammation and disease recurrence.
The Fraunhofer team’s approach differs by inhibiting pathogenic activity rather than eradicating microbes outright. The active compound — guanidinoethylbenzylamino imidazopyridine acetate — selectively blocks the growth of harmful bacteria such as Porphyromonas gingivalis, preventing them from exerting toxic effects while allowing beneficial species to repopulate and restore microbial balance.
Spin-off company
The technology has been commercialized through spin-off company PerioTrap Pharmaceuticals GmbH, which has developed a microbiome-friendly toothpaste and a professional care gel designed for use following dental cleanings. The formulations also include standard preventive components such as fluoride and abrasives.
Development required ensuring the compound was non-toxic, not systemically absorbed, and did not cause tooth discolouration — key barriers to clinical adoption.
Related: U of T startup Mesosil earns FDA clearance for antimicrobial dental biomaterial
The research was conducted under Good Laboratory Practice (GLP) standards, supporting regulatory credibility and potential international uptake. Additional products, including mouthwashes and even veterinary applications, are under development.